84%. The biomarker panel is detectable in the urine sediment using standard analytical techniques (e. g. pyro-sequencing as a reliable and fast method to quantify CpG methylation). Due to the easy access to the samples the inventive method is cost-effective and convenient for the patients. Commercial Opportunities: Urinary bladder carcinoma is one of the most common cancers in human and the most expensive tumour in the US and Europe due to the need for lifelong surveillance. Cystoscopy, “the gold standard” for diagnostic evaluation of bladder cancer, is an invasive, time-consuming and cost-intensive method that is little accepted by the patients. Voided urine cytology as non-invasive method has been utilized as an additional diagnostic tool and screening test. However, the limitations of this method are found both in its comparative low sensitivity and its low objectiveness as it is dependent on the evaluation and experience of the observer. There has been great interest in identifying tumour biomarkers for a more sensitive and objective test, but the currently available, approved urine biomarkers cannot be fully recommended for clinical use.
firstname.lastname@example.org | TechnologieAllianz e.V.
Microarray zur Bestimmung der Reaktion von Tumoren auf Anti-Angiogenese-Behandlung
06.12.2016 | TechnologieAllianz e.V.
Verbessertes Nachweisverfahren für ß-hämolysierende pathogene gram-positive Bakterien
05.12.2016 | TechnologieAllianz e.V.
08.12.2016 | Veranstaltungen
07.12.2016 | Veranstaltungen
05.12.2016 | Veranstaltungen
08.12.2016 | Biowissenschaften Chemie
08.12.2016 | Messenachrichten
08.12.2016 | Seminare Workshops